Basurto-Kuba E, Hurtado-López LM, Zaldívar-Ramírez FR, Vázquez-Ortega R

Language: Spanish
References: 14
Page: 22-26
PDF size: 50.87 Kb.

ABSTRACT

Objective:To know whether patients with papillary carcinoma of the thyroid, with regional metastatic activity as first clinical manifestation and without demonstrable lesion in the gland, have some characteristic that might reveal a greater aggressiveness.
Patient and methods:Retrospective, transversal, comparative, analytical study in three groups of patients with papillary cancer of the thyroid: Group 1, with metastases without palpable primary tumor; group 2, with thyroid nodule and palpable adenomegaly at the time of diagnosis; and group 3, patients that had a differentiated cancer of the thyroid and who presented thyroid tumor without adenomegaly. Assessed variables were: age, gender, size of the primary tumor, size of the clinically detected metastatic ganglion, multicentricity, extra-thyroid infiltration, and follow-up time. Statistical analysis consisted of central tendency measures, Student’s t test, chi square test, and multiple variance analysis.
Results:G1 with seven patients, six women and one man, the average size of the metastasis was 3.6 cm; level III in five cases and V in two, multicentric in one. G2 with 79 patients, 74 women and 5 men. Average size of metastasis 5.6 cm; level I in four, II in 33, III in 35, IV in 31, V in 36, VI in 57, and VII in 21 metastatic ganglia. Multicentric in 21, there were 10 recurrences and 2 persistences. G3 with 220 patients, 206 women and 14 men. Multicentric in 4. The multiple variance analysis (ANOVA) of the obtained results demonstrated differences only in multicentricity in groups G1 and G2 with respect to G3.
Conclusion:The presence of multicentric cancer foci in the thyroid gland is more frequent in the cases of differentiated thyroid cancer with regional metastatic activity as the factor of greatest aggressiveness as compared to those that have no regional metastasis.

REFERENCES

1. Nussbaum M, Bukachevsky R. Thyroid carcinoma presenting as a regional neck mass. Head Neck 1990; 12: 114-7.

2. Sanders LE, Rossi RL. Occult well differentiated thyroid carcinoma presenting as a cervical node disease. World J Surg 1955; 19: 642; discussion 646-7.

3. Attie JN, Setzin M, Klein I. Thyroid carcinoma presenting as an enlarged cervical lymph node. Am J Surg 1993; 166: 428-30.

4. Prasad RR, Narasimhan R, Sankaran V, Veliath AJ. Fine-needle aspiration cytology in the diagnosis of superficial lymphadenopathy: an analysis of 2,418 cases. Diagn Cytopathol 1996; 15: 382-6.

5. Gupta AK, Nayar M, Chandra M. Reliability and limitations of fine needle aspiration cytology of lymphadenophaties. An analysis of 1,261 cases. Acta Cytol 1991; 35: 777-83.

6. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid II. Value of prophylactic lymph node excision. Cancer 1970; 26: 1061-4.

7. Noguchi M, Yamada H, Ohta N, Ishida T, Tajiri K, Fujii H, et al. Regional lymph node metastasis in well-differentiated thyroid carcinoma. Int Surg 1987; 72: 100-3.

8. Shaha AR. Management of the neck in thyroid cancer. Otolaryngol Clin North Am 1998; 31: 823-31.

9. Rossi RL, Cady B, Silverman ML, Wool M, Horner TA. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg 1986; 10: 612-22.

10. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102: 1088-95.

11. Appetecchia M, Mecule A, Sciarretta F. A long-standing cystic lymph-node metastasis from occult thyroid carcinoma. J Exp Clin Cancer Res 2002; 21: 137-8.

12. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. Worl J Surg 1994; 18: 559-67; discussion 567-8.

13. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotrophin. Endocr Relat Cancer 2002; 9: 227-47.

14. Baasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002; 128: 825-8.